Silence Therapeutics (SLN) Earnings Analysis

Silence Therapeutics (SLN) next reports earnings on 2026-08-06, consensus EPS -0.13866 USD. Last quarter (2026-05-07) it beat with EPS -0.32 USD vs -0.33 USD est (+3%). It has beaten estimates in 3/7 recent quarters (43%). Trailing P/E -2.74.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does SLN next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.13866 USD
Revenue estimate0.00B

SLN earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.32 USD-0.33 USD+3%Beat
2026-03-05-0.25 USD-0.32 USD+21.9%Beat
2025-11-06-0.45 USD-0.4 USD-12.5%Miss
2025-08-07-0.54 USD-0.27 USD-100%Miss
2025-05-08-0.6 USD-0.18 USD-233.3%Miss
2025-02-270.27 USD-0.45 USD+160%Beat
2024-11-14-0.75 USD-0.42 USD-78.6%Miss

Beat rate: 3/7 (43%) over reported quarters with consensus data.

SLN valuation and analyst view

Trailing P/E-2.74
Trailing EPS-1.80322 USD
Price / book11.31
Dividend yield0.00%
Market cap0.54B
Analyst consensusBuy (4 buy / 0 hold / 1 sell)

Related research pages

Frequently asked questions

When is Silence Therapeutics (SLN)'s next earnings date?

Silence Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.13866 USD and revenue estimate of 0.00B.

Did SLN beat earnings last quarter?

In its 2026-05-07 report, SLN posted EPS of -0.32 USD versus a -0.33 USD estimate — a beat of 3%.

What is SLN's earnings track record?

Over the last 7 reported quarters with consensus data, SLN beat estimates 3 times (43%).

What is SLN's current P/E ratio and EPS?

SLN trades at a trailing P/E of -2.74 on trailing EPS of -1.8032223732725599 USD.

What do analysts rate SLN?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 4 buy, 0 hold, 1 sell, 0 strong sell).